December 18, 2019
WELLESLEY, Mass., Dec. 18, 2019– The chronic disease market is fuelled by a superior clinical results of new drugs and biologics, increasing trend of digital health and the U.S. Patient Protection and Affordable Care Act, according to a report by BCC Research, "Chronic Disease Management: Therapeutics, Device Technologies and Global Markets.”
The market for chronic disease management expects to see a compound annual growth rate (CAGR) of 7.2% through 2024, when it could be worth $490 billion.
Major players in the market include: Agenus (AGEN), Apotex and Philosys.
Research Highlights
Read the full report here: https://www.bccresearch.com/market-research/healthcare/chronic-disease-management-market-report.html
“Chronic diseases are complex in nature and need long-term treatment and care in hospitals and within home care, according to BCC Research analyst Dr. Ritu Thakur. “Home care accounts for the largest share of the chronic disease therapeutics and device technologies market, followed by hospitals and other settings.”
Therapeutics to See Continued Growth Due to Innovative Drugs and Wearable Devices
Therapeutics has witnessed significant progress in the past two decades, and the trend is expected to continue with new and innovative drugs and biologics targeting unmet needs. With recent technological advances, advanced wearable device technologies and improved treatment adherence solutions are beginning to enter the mainstream management solutions for chronic diseases, in addition to therapeutics.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets( HLC239A )
Publish Date: Nov 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.